ClinicalTrials.gg
RecruitingNCT00825929PANNAUpdated Jan 13, 2025

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

An observational study in HIV Infections, sponsored by Radboud University Medical Center. Recruiting at 21 sites in 7 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by Radboud University Medical Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
176
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in HIV Infections by Radboud University Medical Center — 1 open to participants now, 1 under way, none of them phase 3. HIV Infections · Radboud University Medical Center.

Started
2009
with 3 others
Observational
3 of 17
1 open now
Registered
10th of 17
by date

Among the 17 studies in HIV Infections by Radboud University Medical Center, this one is one of 4 that started in 2009, is one of 3 observational ones, and was the 10th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 17 studies in HIV Infections by Radboud University Medical Center is open now, in 7 countries.

By country, each count listing its studies:

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in HIV Infections by Radboud University Medical Center, or all of them as a file.
02

Study summary

Due to the potential for pregnancy-induced changes in the pharmacokinetics of medication, one cannot assume that the currently licensed doses of the medication to be tested under this protocol lead to adequate exposure in an HIV-infected pregnant woman. For the agents under study no or limited pharmacokinetic data during pregnancy are available. As the changes in pharmacokinetics during pregnancy are most prominent in the third trimester a pharmacokinetic curve will be recorded in the third trimester after attaining steady state.

Read the detailed description

The following agents will be studied:

Etravirine, Intelence, TMC125; Emtricitabine, Emtriva or FTC; Tenofovir, Viread, TDF; Atazanavir, Reyataz; Fosamprenavir, Telzir, FPV; Darunavir, Prezista, TMC114; Tipranavir, Aptivus, TPV; Indinavir, Crixivan; abacavir; raltegravir, Isentress; Enfuvirtide, Fuzeon; Maraviroc, Celsentri; dolutegravir; elvitegravir/cobicistat; rilpivirine, TAF, darunavir/cobicistat; doravirine; bictegravir; cabotegravir/rilpivirine long acting injectables

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • pharmacokinetics
  • pregnancy
  • antiretrovirals
  • neonates
  • HIV
  • treatment experienced
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

HIV-infected pregnant women using at least one of the following antiretroverial agents: Etravirine, Intelence, TMC125; Emtricitabine, Emtriva or FTC; Tenofovir, Viread, TDF; Atazanavir, Reyataz; Fosamprenavir, Telzir, FPV; Darunavir, Prezista, TMC114; Tipranavir, Aptivus, TPV; Indinavir, Crixivan; abacavir; raltegravir, Isentress; Enfuvirtide, Fuzeon; Maraviroc, Celsentri; dolutegravir; elvitegravir/cobicistat; rilpivirine, TAF, darunavir/cobicistat; doravirine; bictegravir; cabotegravir/rilpivirine LA

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. -infected as documented by positive HIV antibody test and confirmed by an antigen test.
  2. Subject is at least 18 years of age at screening.
  3. Subject is able and willing to sign the Form prior to screening evaluations.
  4. Treated with a cART regimen containing at least one agent which is mentioned in Appendix 1; this agent has been taken for at least 2 weeks before the day of first PK curve evaluation.
  5. Subject is pregnant
  6. Subject is able to adhere to food intake recommendations, if applicable.

Exclusion criteria

Exclusion Criteria:

  1. Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.
  2. Inability to understand the nature and extent of the study and the procedures required.
  3. Presence of grade III/IV anemia (i.e. \<4.6 mmol/L or \<7.4 g/dL).
  4. Using oral cabotegravir/rilpivirine.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
176 participants (estimated)
Biospecimen retention
Samples without dna

Groups and cohorts

  • 1

    Treated with one of the antiretroviral agents under study, PK parameters during pregnancy will be compared with PK parameters after pregnancy (within the same woman)

06

What researchers measure

Primary outcomes

  1. Plasma concentrations of the compounds during pregnancy compared to the concentrations after delivery

    Time frame: PK curve in Week 33 of pregnancy and 4-6 weeks after delivery

Secondary outcomes

  1. Pharmacokinetics in the neonate, in case of post-exposure prophylaxis with one of the agents under study.

    Time frame: Week 1, 3 and between 4 and 6

  2. Safety of antiretrovirals during pregnancy

    Time frame: GA Week 33 until end of trial

  3. viral load response and prevention of mother to child transmission of the virus

    Time frame: GA Week 3 and at delivery

07

Study locations

16 of 21 sites recruiting
  • Saint-Pierre University Hospital; Department of Infectious Diseases
    Brussels, Belgium
    Recruiting
    • D Konopnicki · Contact
    • D Konopnicki, MD · Principal investigator
  • CHARITÉ Berlin
    Berlin, Germany
    Recruiting
  • University of Bonn
    Bonn, Germany
    Recruiting
    • Juergen Rockstroh, MD, PhD · Principal investigator
  • University of Cologne
    Cologne, Germany
    Recruiting
    • J Malin · Principal investigator
  • Johann Wolfgang Goethe-Universität
    Frankfurt am Main, Germany
    Recruiting
  • University München
    München, Germany
    Recruiting
    • B Kost · Contact
    • B Kost, MD · Principal investigator
  • Mater Hospital and UCD
    Dublin, Ireland
    Recruiting
    • John Lambert · Contactjlambert@mater.ie
    • John Lambert, MD · Principal investigator
  • St James's Hospital Dublin
    Dublin, Ireland
    Recruiting
  • IRCSS
    Rome, Italy
    Completed

    Not enrolling at this site — choose another above.

  • AMC
    Amsterdam, Netherlands
    Completed

    Not enrolling at this site — choose another above.

  • Radboud University Nijmegen Medical Centre
    Nijmegen, Netherlands
    Recruiting
    • van Crevel, Md. PhD · Principal investigator
  • Erasmus Medical Center Rotterdam
    Rotterdam, Netherlands
    Recruiting
    • Rokx, MD, PhD · Principal investigator
  • St Elisabeth hospital
    Tilburg, Netherlands
    Recruiting
    • Marjo van Kasteren · Contact
    • Marjo van Kasteren · Principal investigator
  • Hospital Universitari Germans Trias i Pujol, Badalona
    Badalona, Spain
    Recruiting
    • Jose Molto, MD, PhD · Principal investigator
  • Hospital Universitario Virgen de las Nieves Granada; Médico Adjunto del Servicio de Medicina Interna
    Granada, Spain
    Recruiting
  • Brighton and Sussex University Hospitals NHS Trust
    Brighton, United Kingdom
    Recruiting
    • Yvonne Gilleece · Contact
    • Yvonne Gilleece · Principal investigator
  • C&W Hospital, London
    London, United Kingdom
    Recruiting
    • David Hawkins, MD, PhD · Principal investigator
  • North Middlesex Hospital
    London, United Kingdom
    Completed

    Not enrolling at this site — choose another above.

  • St Mary's Hospital, London
    London, United Kingdom
    Recruiting
    • Graham Taylor, MD, PhD · Principal investigator
  • St Thomas Hospital
    London, United Kingdom
    Withdrawn

    Not enrolling at this site — choose another above.

  • St. George's Hospital, London
    London, United Kingdom
    Completed

    Not enrolling at this site — choose another above.

08

References and documents

Publications

  • Colbers AP, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, Weizsacker K, Sadiq ST, Ivanovic J, Giaquinto C, Taylor GP, Molto J, Burger DM; PANNA network. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS. 2013 Mar 13;27(5):739-48. doi: 10.1097/QAD.0b013e32835c208b. PubMed 23169329 ↗
  • Colbers A, Gingelmaier A, van der Ende M, Rijnders B, Burger D. Pharmacokinetics, safety and transplacental passage of rilpivirine in pregnancy: two cases. AIDS. 2014 Jan 14;28(2):288-90. doi: 10.1097/QAD.0000000000000100. No abstract available. PubMed 24413315 ↗
  • Bollen P, Freriksen J, Konopnicki D, Weizsacker K, Hidalgo Tenorio C, Molto J, Taylor G, Alba-Alejandre I, van Crevel R, Colbers A, Burger D; Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women Network. The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021 Jan 23;72(1):121-127. doi: 10.1093/cid/ciaa006. PubMed 32103260 ↗
  • Bukkems V, Necsoi C, Tenorio CH, Garcia C, Rockstroh J, Schwarze-Zander C, Lambert JS, Burger D, Konopnicki D, Colbers A. Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network. Clin Infect Dis. 2020 Dec 17;71(10):e714-e717. doi: 10.1093/cid/ciaa488. PubMed 32330231 ↗
  • Kreitchmann R, Schalkwijk S, Best B, Wang J, Colbers A, Stek A, Shapiro D, Cressey T, Mirochnick M, Burger D. Efavirenz pharmacokinetics during pregnancy and infant washout. Antivir Ther. 2019;24(2):95-103. doi: 10.3851/IMP3283. PubMed 30530925 ↗
  • Schalkwijk S, Colbers A, Konopnicki D, Gingelmaier A, Lambert J, van der Ende M, Molto J, Burger D; Pharmacokinetics of newly developed antiretroviral agents in HIV-infected pregnant women (PANNA) Network. Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women. Clin Infect Dis. 2017 Oct 15;65(8):1335-1341. doi: 10.1093/cid/cix534. PubMed 28595298 ↗
  • Mulligan N, Schalkwijk S, Best BM, Colbers A, Wang J, Capparelli EV, Molto J, Stek AM, Taylor G, Smith E, Hidalgo Tenorio C, Chakhtoura N, van Kasteren M, Fletcher CV, Mirochnick M, Burger D. Etravirine Pharmacokinetics in HIV-Infected Pregnant Women. Front Pharmacol. 2016 Aug 4;7:239. doi: 10.3389/fphar.2016.00239. eCollection 2016. PubMed 27540363 ↗
  • Colbers A, Best B, Schalkwijk S, Wang J, Stek A, Hidalgo Tenorio C, Hawkins D, Taylor G, Kreitchmann R, Burchett S, Haberl A, Kabeya K, van Kasteren M, Smith E, Capparelli E, Burger D, Mirochnick M; PANNA Network and the IMPAACT 1026 Study Team. Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. Clin Infect Dis. 2015 Nov 15;61(10):1582-9. doi: 10.1093/cid/civ587. Epub 2015 Jul 22. PubMed 26202768 ↗
  • Blonk MI, Colbers AP, Hidalgo-Tenorio C, Kabeya K, Weizsacker K, Haberl AE, Molto J, Hawkins DA, van der Ende ME, Gingelmaier A, Taylor GP, Ivanovic J, Giaquinto C, Burger DM; Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women PANNA Network; PANNA Network. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy. Clin Infect Dis. 2015 Sep 1;61(5):809-16. doi: 10.1093/cid/civ366. Epub 2015 May 5. PubMed 25944344 ↗
  • Colbers A, Molto J, Ivanovic J, Kabeya K, Hawkins D, Gingelmaier A, Taylor G, Weizsacker K, Sadiq ST, Van der Ende M, Giaquinto C, Burger D; PANNA Network. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women. J Antimicrob Chemother. 2015 Feb;70(2):534-42. doi: 10.1093/jac/dku400. Epub 2014 Oct 17. PubMed 25326090 ↗
  • Colbers A, Hawkins D, Hidalgo-Tenorio C, van der Ende M, Gingelmaier A, Weizsacker K, Kabeya K, Taylor G, Rockstroh J, Lambert J, Molto J, Wyen C, Sadiq ST, Ivanovic J, Giaquinto C, Burger D; PANNA network. Atazanavir exposure is effective during pregnancy regardless of tenofovir use. Antivir Ther. 2015;20(1):57-64. doi: 10.3851/IMP2820. Epub 2014 Jul 3. PubMed 24992294 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2009
First posted
Jan 21, 2009
Start
Feb 2009
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00825929
Responsible party
Sponsor
First posted
Jan 21, 2009
Start date
Feb 2009
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 13, 2025

Study contacts

David M Burger, PharmD PhD
Contact
david.burger@radboudumc.nl
++31 24 3616405
Wendy van der Wekken, MSc
Contact
David M Burger, PharmD PhD
principal investigator · Radboud University Medical Centre Nijmegen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion